Oxford Cannabinoid Technologies (“OCT”), a UK-based biotechnology firm researching the potential of cannabinoids for treating a range of acute and chronic conditions, today announces the appointment of Dr Valentino Parravicini PhD as its new Chief Scientific Officer (“CSO”).
Dr Parravicini has joined the business to support the delivery of its objective to become a global leader in developing cannabinoid-based prescription medicine for indications in oncology, pain, immunology and neurology.
Dr Parravicini will oversee all of OCT’s ongoing drug discovery and development studies, including pre-clinical development of OCT461201, the company’s lead, highly selective and potent CB2 agonist, believed to be a potentially effective treatment for Irritable Bowel Syndrome (“IBS”) and other diseases. He will work closely with OCT’s lead business and research partners, while developing new research partnerships with other leading academic and commercial institutions around the world.
Dr Parravicini has a long and distinguished career in the fields of oncology, inflammation and immunology. He has led ground-breaking in vitro and in vivo projects and undertaken award-winning work in pharma and biotech focussed on small molecule and cell therapy approaches to autoimmunity and haematological malignancies. He is also an extensively published author on his discoveries and innovations with high-impact peer-reviewed publications in the fields of immunology and molecular virology.
Date posted: 23 July 2020
Article tag: Oxford Cannabinoid Technologies
Share